Navigation Links
Landmark Research Heralds New Era in Dog Heart Treatment and Longer Life for Dogs

INGELHEIM, Germany, September 11 /PRNewswire/ --

- For Non-US Healthcare Media

- Global QUEST Study Reveals Dogs With Congestive Heart Failure Have Significantly Improved Survival Outcomes With Vetmedin(R) (pimobendan)

Veterinarians and dog owners are today welcoming new research that delivers the promise of an extended happy life together for millions of dog owners and their pets. The three-year study demonstrates that dogs suffering from the most common type of heart failure live on average 91% (267 days vs. 140 days) longer when treated with the product Vetmedin(R) (pimobendan) compared with another common treatment option(1).

To view the Multimedia News Release, go to:

Results from the QUEST (Quality of Life and Extension of Survival Time) study, published in the current issue of the Journal of Veterinary Internal Medicine, mark a significant milestone in canine cardiac health. Experts report that 25% of all small to medium-sized dogs over the age of seven are likely to suffer from heart disease at some point in their life(2), and 75% of those cases are caused by myxomatous mitral valve disease (MMVD)(3), sometimes known as "valvular insufficiency" or "endocardiosis".

Adrian Boswood from the Royal Veterinary College, London, a Veterinary Cardiology Specialist and a lead-investigator on the study, explains that the independent QUEST trial set out to explore the impact on survival of Vetmedin(R) versus another current treatment, benazepril hydrochloride, an angiotensin-converting enzyme (ACE) inhibitor.

"With QUEST demonstrating that dogs treated with Vetmedin(R) live on average nearly twice as long as those on benazepril(1), it is now time for us as veterinary cardiologists and practising veterinarians to look again at how we are treating our patients suffering from this serious condition."

Dr. Michael O'Grady from the Ontario Veterinary College, University of Guelph, a fellow lead-investigator added, "The QUEST study provides compelling evidence that dogs with the most common form of heart failure should be receiving Vetmedin(R) as an essential part of their treatment regimen."

QUEST is the largest international study ever conducted looking at treatment for congestive heart failure (CHF) caused by MMVD, with 260 dogs studied in 11 countries, across three continents, over a period of three years.

The study was conducted by a team of 32 independent veterinary cardiologists from Australia, Canada, France, Germany and the United Kingdom among other countries.

CHF caused by MMVD most commonly affects older, small breed dogs, including Cavalier King Charles Spaniels, Poodles, Chihuahuas and Dachshunds.(3)

Symptoms of this form of heart failure that dog owners should look for include coughing, reduced tolerance for exercise, anxiety and restlessness during the night, and laboured breathing.(3) If these symptoms are present, it is important that dog owners take their pets to their veterinarians for assessment and treatment.

"Dog owners should be encouraged by the results of the QUEST study, as it demonstrates an important treatment option for lengthening a dog's life when it has this common, debilitating and life-threatening heart condition," said Jens Häggström, Professor of Veterinary Internal Medicine, University of Uppsala and the other lead-investigator on the trial.

Owners now have new information regarding the best chance for enjoying the maximum time possible with their dogs suffering from the most common cause of heart failure.

"With our dogs being so important to our families, we owners should do all we can to make sure our pets are receiving the most effective treatment", said Sally Copland, owner of Fern, an eight-year-old King Charles Spaniel being treated with Vetmedin(R). "None of us want our pets' lives unnecessarily cut short," she added.

The full QUEST study results, providing hard evidence about the importance of using Vetmedin, appear in the September/October 2008 issue of the Journal of Veterinary Internal Medicine.

For more information on the QUEST study and on CHF caused by MMVD, please visit

Boehringer Ingelheim

Boehringer Ingelheim Animal Health and Boehringer Ingelheim Vetmedica belong to the Boehringer Ingelheim group of companies. The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 135 affiliates in 47 countries and 39,800 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

In 2007, Boehringer Ingelheim posted net sales of almost 11 billion euro while spending one fifth of net sales in its largest business segment, Prescription Medicines, on research and development.

The animal health business is conducted in more than 20 countries including USA, Canada, France, Germany, UK, Italy, Spain, Mexico, the Nordic countries Japan and China. Since 1955, Boehringer Ingelheim Animal Health is contributing to an adequate supply of safe, nutritious food and is promoting the emotional and physical benefits arising from the human-animal bond.

For more information, please visit



(1) Häggström J, Boswood A, O'Grady M et al. Effect of Pimobendan or Benazepril Hydrochloride on Survival Times in Dogs with Congestive Heart Failure Caused by Naturally Occurring Myxomatous Mitral Valve Disease: The QUEST Study. J Vet Intern Med. 2008;22(5).

(2) Evans T, Johnson C, Wernham J. Cardiovascular Insight: A global study of category prospects. Wood Mackenzie. July 2007.

(3) Häggström J, Kvart C and Pedersen H. "Acquired valvular heart disease" in Ettinger SJ, Feldman EC (Eds). Textbook of veterinary internal medicine: diseases of the dog and cat. 2005 (6th edition).

SOURCE Boehringer Ingelheim Animal Health
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Senator Bob Dole to Hold Landmark Health Care Forum at Dole Institute of Politics in Kansas
2. Senate Passes Landmark AIDS, TB and Malaria Bill, Says Global AIDS Alliance
3. Kidney Community Thanks Congress for Passing Landmark End Stage Renal Disease (ESRD) Reform
4. Pfizers work on penicillin for World War II becomes a National Historic Chemical Landmark
5. International Training and Development Company, Landmark Education, Mischaracterized as Religion
6. House Passes Landmark Bill on RN Staffing and Patient Safety in Massachusetts Hospitals
7. AAAS, FDLI Sponsor Landmark Meeting on Personalized Medicine June 20, 2008
8. Boston Scientific Completes Enrollment in Landmark Heart Failure Trial
9. Landmark Study Aims to Improve Osteoporosis Care Standards Worldwide
10. Reps. Smith and Doyle, Autism Society of America Push Landmark Legislation on World Autism Awareness Day
11. Landmark Pediatric Allergies in America Survey Uncovered Negative Impact of Allergy Symptoms on Children
Post Your Comments:
(Date:6/27/2016)... ... June 27, 2016 , ... recently awarded their highest five-star ... , Millions of individuals in the United States and Canada wear eyeglasses. Once considered ... both correct vision and make a fashion statement. Even celebrities use glasses as a ...
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... Pixel Film ... Pro X. , "Film editors can give their videos a whole new perspective by ... Austin - CEO of Pixel Film Studios. , ProSlice Levels contains over 30 ...
(Date:6/26/2016)... ... June 26, 2016 , ... ... have been diagnosed with endometriosis. These women need a treatment plan to not ... comprehensive approach that can help for preservation of fertility and ultimately achieving a ...
(Date:6/25/2016)... ... 2016 , ... The temporary closing of Bruton Memorial Library on June 21 due to a ... new, often overlooked aspect of head lice: the parasite’s ability to live away from a ... occurrence, but a necessary one in the event that lice have simply gotten out of ...
(Date:6/25/2016)... ... 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned ... the David Geffen School of Medicine at UCLA. He trained in Internal Medicine at ... fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)...  VMS Rehab Systems, Inc. ( ) reported ... required to build a strong and stable market for ... on the OTC Markets-pink current trading platform. ... are seeing an anomaly in market trading activities that ... the Company, but shareholders and market players as well. ...
(Date:6/24/2016)... June 24, 2016   Bay Area Lyme ... Dean Center for Tick Borne Illness , ... Rehabilitation, MIT Hacking Medicine, University of California, Berkeley, ... announced the five finalists of Lyme Innovation ... More than 100 scientists, clinicians, researchers, entrepreneurs, and ...
(Date:6/24/2016)... SAN CLEMENTE, Calif. , June 24, 2016  American ... function testing company, is now able to perform sophisticated lung assessments ... ndd Medical Technologies , Inc. Patients are no ...  Thanks to ndd,s EasyOne PRO ® , ARL patients like Jeanne ... needed testing done in the comfort of her own home. ...
Breaking Medicine Technology: